Synopsis

Source of validity: Scientific
Rating (out of 5): 1

Akkermansia muciniphila is a gut bacterium that has drawn scientific interest for its potential role in metabolic health and, more recently, neurodegenerative diseases such as Alzheimer’s Disease (AD). The interest stems from the emerging concept of the “gut-brain axis,” which suggests that gut microbiota can influence brain function and neuroinflammation. However, the evidence supporting the use of Akkermansia muciniphila specifically to treat or support Alzheimer’s Disease is currently limited and mostly preclinical.

Animal studies have demonstrated that Akkermansia muciniphila supplementation can improve cognitive deficits and reduce neuroinflammation in mouse models of Alzheimer’s Disease. For example, some research indicates that these effects may be mediated by the bacterium’s ability to enhance gut barrier function, reduce systemic inflammation, and modulate metabolites that influence neuroinflammatory pathways. In addition, altered levels of A. muciniphila have been observed in the gut microbiota of patients with AD compared to healthy controls, but it is not clear whether these changes are a cause or a consequence of the disease.

Despite promising preclinical findings, there are currently no robust human clinical trials demonstrating that supplementation with Akkermansia muciniphila can prevent, treat, or meaningfully alter the course of Alzheimer’s Disease. For this reason, the evidence rating is low (1/5), and use is justified by early scientific exploration rather than established clinical benefit or traditional use.

More about Akkermansia muciniphila
More about Alzheimer's Disease

Other ingredients used for Alzheimer's Disease

Other health conditions supported by Akkermansia muciniphila

Products containing Akkermansia muciniphila

Metagenics Akkermansia Co.™ Healthy Weight with Glucose Control
Metagenics UltraFlora Triplebiotic